These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds. Porskjær Christensen L; Bahij El-Houri R Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999 [TBL] [Abstract][Full Text] [Related]
26. KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. Kim KR; Lee JH; Kim SJ; Rhee SD; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG Biochem Pharmacol; 2006 Aug; 72(4):446-54. PubMed ID: 16797489 [TBL] [Abstract][Full Text] [Related]
27. Skp2 promotes adipocyte differentiation via a p27Kip1-independent mechanism in primary mouse embryonic fibroblasts. Okada M; Sakai T; Nakamura T; Tamamori-Adachi M; Kitajima S; Matsuki Y; Watanabe E; Hiramatsu R; Sakaue H; Kasuga M Biochem Biophys Res Commun; 2009 Feb; 379(2):249-54. PubMed ID: 19109928 [TBL] [Abstract][Full Text] [Related]
28. Regulation effects of TZQ-F on adipocyte differentiation and insulin action. Nan Xia J; Qin Zhang D; Du J; Wen J J Ethnopharmacol; 2013 Nov; 150(2):692-9. PubMed ID: 24095827 [TBL] [Abstract][Full Text] [Related]
30. Porcine peroxisome proliferator-activated receptor gamma induces transdifferentiation of myocytes into adipocytes. Yu YH; Liu BH; Mersmann HJ; Ding ST J Anim Sci; 2006 Oct; 84(10):2655-65. PubMed ID: 16971566 [TBL] [Abstract][Full Text] [Related]
31. A study of cardiovascular function in Tsumura Suzuki obese diabetes, a new model mouse of type 2 diabetes. Kawada T; Miyata S; Shimada T; Sanzen Y; Ito M; Hemmi C; Iizuka S; Suzuki W; Mihara K; Aburada M; Nakazawa M Biol Pharm Bull; 2010; 33(6):998-1003. PubMed ID: 20522966 [TBL] [Abstract][Full Text] [Related]
32. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887 [TBL] [Abstract][Full Text] [Related]
34. Possible involvement of hypothalamic nucleobindin-2 in hyperphagic feeding in Tsumura Suzuki obese diabetes mice. Miyata S; Yamada N; Kawada T Biol Pharm Bull; 2012; 35(10):1784-93. PubMed ID: 23037168 [TBL] [Abstract][Full Text] [Related]
35. Licochalcone E has an antidiabetic effect. Park HG; Bak EJ; Woo GH; Kim JM; Quan Z; Kim JM; Yoon HK; Cheon SH; Yoon G; Yoo YJ; Na Y; Cha JH J Nutr Biochem; 2012 Jul; 23(7):759-67. PubMed ID: 21840191 [TBL] [Abstract][Full Text] [Related]
36. A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Camp HS; Chaudhry A; Leff T Endocrinology; 2001 Jul; 142(7):3207-13. PubMed ID: 11416043 [TBL] [Abstract][Full Text] [Related]
37. Very low density lipoprotein receptor promotes adipocyte differentiation and mediates the proadipogenic effect of peroxisome proliferator-activated receptor gamma agonists. Tao H; Hajri T Biochem Pharmacol; 2011 Dec; 82(12):1950-62. PubMed ID: 21924248 [TBL] [Abstract][Full Text] [Related]